DRAMI: No Clear Winner for Distal vs Traditional Radial Access in STEMI dlvr.it/TFrVNQ

#TCT2024 📌Estudio interesante que refleja algo que llevamos haciendo un tiempo en HemodinamicaH12O ✅Cierre vascular post-TAVI con 1Proglide + 1Angioseal superior a 2Proglide, sobre todo a expensas de sangrados menores 👇🏻👇🏻 ✅Implicaciones 💴 ACI-SEC: Hemodinamica

Defining bleeding risk in TAVR patients. Validation of the Valve Academic Research Consortium High Bleeding Risk Definition published simultaneously Cardiovascular Research Foundation #TCT2024 ahajournals.org/doi/10.1161/CI… Marisa Avvedimento Pedro Cepas IUCPQ-ULaval #AHAJournals #Cardiotwitter

PROTECT TAVI done - trial negative

#Evoque #TTVR #TRISCEND2 RCT showed no diff in ☠️HFH but ⬆️KCCQ 6MWD. Landmark analysis showed trend in ⬇️☠️in TTVR but not powered. Papers now in NEJM JACC Journals #TCT2024 Cardiovascular Research Foundation RTHahnMD Susheel Kodali, MD

ACURATE IDE trial comparing ACURATE NEO 2 valve w/ commercially available TAVR valves in pts w/ severe AS shows ACURATE Neo 2 was not non-inferior to commercially available valves! COVID, early experience, and low volumes may have played a role in this; #LBCT #TCT2024 Cardiovascular Research Foundation

In pts with intermediary coronary stenosis, a QFR-guided strategy was associated with worse prognosis after one year, than a standard FFR guided strategy (FAVOR 3 Europe). Still, QFR is superior to "eyeballing" (FAVOR 3 China). Niels R. Holm The Lancet #TCT2024 GACI

TAVI Wars, Episode III. Troubling data for the Acurate neo2 in the regulatory trial just presented here at #TCT2024 (currently unpublished), with increased cardiac mortality (as had occurred with the first-generation valve in our SCOPE 2 trial) and stroke, with noninferiority not

#TCT2024 #LBCT TRISCEND II Cardiovascular Research Foundation At 1 year, TRISCEND Il demonstrated superiority of EVOQUE TTVR TTVR with EVOQUE led to sustained TR reduction to ≤ mild in all patients Significant improvement in symptoms, function, & QOL at 1 year with favorable numerical trends in

1/x #QFR did not meet non-inferiority to FFR in the The FAVOR III trial Europe presented by Birgitte Krogsgaard The 1-year primary EP of death, MI, and unplanned revasc was 6.7% vs 4.2% in favour of FFR. 21% more study-lesions were treated- and 27% more stents were implanted with QFR due

⁦Mamas A. Mamas⁩ summarizes the outcomes of ⁦The FAVOR III trial⁩

Another GLP-1 success, semaglutide for relief of knee osteoarthritis in people with obesity, a randomized trial NEJM nejm.org/doi/full/10.10…

Among participants with obesity and pain related to knee osteoarthritis, treatment with weekly semaglutide for 68 weeks resulted in greater reductions in body weight and knee pain than placebo. Full STEP 9 trial results: nej.md/40oSLHB

Great talk by Sarah Fairley about real time ivus-guided ostial stenting. #TCT2024 neat technique very well depicted by her.

ACURATE IDE trial failed to demonstrate non-inferiority of Acurate Neo2 platform against Evolute & Sapien valves, many discussion behind the results (20% of underexpanded valves, bad implantation technique, COVID delayed patient inclusion) #TCT2024

Mi opinión respecto a este debate importantísimo que propone Kiko Llaneras: Las redes sociales son un medio super-hostil para "comunicar incertidumbre". ¿Por qué? Porque el algoritmo premia las afirmaciones contundentes, los juicios tajantes. ¿Por qué premia eso? Porque está

Abiomed’s Impella ECP Pivotal Study Investigates Safety, Efficacy for Use in High-Risk PCI | Johnson & Johnson MedTech | Heart Recovery citoday.com/news/abiomeds-…

The optimal revascularization strategy in patients with ischaemic cardiomyopathy remains unclear. New large registry study investigates long-term survival in patients with severe ischaemic cardiomyopathy revascularized by #CABG / #PCI #CAD #cardiotwitter, European Society of Cardiology Journals, European Society of Cardiology

The Hostile score proved useful in predicting nonpuncture vascular complications after #TAVR. An integrated approach is warranted to further reduce the risk of vascular access site complications after TAVR. bit.ly/4egrXg5 #JACCINT Thomas Pilgrim

Comparison of strategies for vascular ACCESS closure after transcatheter aortic valve implantation. Read the ACCESS-TAVI randomised trial in #EHJ 👉 bit.ly/48zn5Sd Rocco Montone EHJ Editor-in-Chief #TAVI